Short Interest in Marker Therapeutics, Inc. (NASDAQ:MRKR) Grows By 43.5%

Marker Therapeutics, Inc. (NASDAQ:MRKR) saw a large increase in short interest in December. As of December 15th, there was short interest totaling 335,196 shares, an increase of 43.5% from the November 30th total of 233,661 shares. Currently, 2.2% of the company’s stock are short sold. Based on an average trading volume of 311,655 shares, the days-to-cover ratio is presently 1.1 days. Based on an average trading volume of 311,655 shares, the days-to-cover ratio is presently 1.1 days. Currently, 2.2% of the company’s stock are short sold.

Marker Therapeutics Stock Up 5.9%

Shares of NASDAQ MRKR traded up $0.09 during trading on Monday, reaching $1.52. 429,021 shares of the company traded hands, compared to its average volume of 642,898. The firm has a 50 day simple moving average of $1.15 and a 200-day simple moving average of $1.21. Marker Therapeutics has a 52-week low of $0.81 and a 52-week high of $4.07. The stock has a market capitalization of $25.34 million, a PE ratio of -1.24 and a beta of 1.35.

Marker Therapeutics (NASDAQ:MRKR) last issued its quarterly earnings data on Thursday, November 13th. The company reported ($0.12) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.69) by $0.57. Marker Therapeutics had a negative net margin of 304.56% and a negative return on equity of 92.35%. The company had revenue of $1.23 million for the quarter, compared to the consensus estimate of $0.72 million. As a group, research analysts predict that Marker Therapeutics will post -0.65 EPS for the current year.

Institutional Trading of Marker Therapeutics

A number of hedge funds have recently bought and sold shares of MRKR. Two Sigma Investments LP bought a new position in Marker Therapeutics in the third quarter valued at about $33,000. Jane Street Group LLC bought a new position in shares of Marker Therapeutics in the 2nd quarter worth approximately $33,000. Finally, Virtu Financial LLC bought a new position in shares of Marker Therapeutics in the 3rd quarter worth approximately $25,000. Hedge funds and other institutional investors own 22.39% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts recently weighed in on MRKR shares. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Marker Therapeutics in a research report on Monday, December 22nd. Wall Street Zen lowered Marker Therapeutics from a “hold” rating to a “sell” rating in a research report on Sunday, November 30th. Zacks Research raised shares of Marker Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, November 18th. HC Wainwright began coverage on shares of Marker Therapeutics in a report on Monday, December 8th. They issued a “buy” rating and a $10.00 target price for the company. Finally, UBS Group reiterated a “buy” rating on shares of Marker Therapeutics in a research note on Monday, December 8th. Three analysts have rated the stock with a Strong Buy rating, three have issued a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Buy” and an average price target of $10.17.

Marker Therapeutics Company Profile

Marker Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of personalized T-cell immunotherapies for cancer. The company’s proprietary Maestro™ platform is designed to isolate, expand and activate a patient’s own T-cells against multiple tumor-associated antigens simultaneously. By leveraging next-generation sequencing and advanced cell processing techniques, Marker aims to overcome tumor immune evasion and deliver targeted immune responses in solid tumors and hematologic malignancies.

Marker’s lead programs include autologous T-cell therapies engineered to recognize viral-associated and self-antigens that are overexpressed in certain cancers.